Insider Transactions in Q1 2025 at Soleno Therapeutics Inc (SLNO)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2025
|
Matthew Pauls |
SELL
Open market or private sale
|
Direct |
5,937
-47.74%
|
$421,527
$71.55 P/Share
|
|
Mar 28
2025
|
Matthew Pauls |
BUY
Exercise of conversion of derivative security
|
Direct |
5,937
+32.31%
|
$23,748
$4.6 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
27,662
-14.46%
|
$1,908,678
$69.87 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
2,691
+4.4%
|
$88,803
$33.6 P/Share
|
|
Mar 28
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
333,557
-6.96%
|
$23,348,990
$70.6 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
90,622
-5.78%
|
$6,252,918
$69.46 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+8.63%
|
$630,000
$9.22 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
45,249
-6.82%
|
$3,122,181
$69.03 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+31.0%
|
$1,702,000
$46.31 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
95,500
-12.43%
|
$6,494,000
$68.71 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
BUY
Exercise of conversion of derivative security
|
Direct |
40,638
+11.97%
|
$162,552
$4.25 P/Share
|
|
Mar 27
2025
|
Michael F. Huang Sr. VP of Clinical Development |
SELL
Open market or private sale
|
Direct |
14,583
-3.66%
|
$1,006,227
$69.36 P/Share
|
|
Mar 27
2025
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.6%
|
$210,000
$21.93 P/Share
|
|
Mar 27
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
699,095
-6.94%
|
$47,538,460
$68.58 P/Share
|
|
Mar 27
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
523,809
+8.49%
|
$7,857,135
$15.9 P/Share
|
|
Mar 27
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
128,653
-9.36%
|
$8,877,057
$69.23 P/Share
|
|
Mar 27
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
72,140
+7.83%
|
$721,400
$10.74 P/Share
|
|
Mar 27
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,100,000
-18.67%
|
$73,700,000
$67.8 P/Share
|
|
Mar 26
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-6.36%
|
$26,000,000
$65.8 P/Share
|
|
Jan 21
2025
|
Patricia C Hirano |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+5.39%
|
-
|
|
Jan 21
2025
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+13.39%
|
-
|
|
Jan 21
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+10.34%
|
-
|
|
Jan 21
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,600
+20.24%
|
-
|
|
Jan 21
2025
|
Kristen Yen |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+7.16%
|
-
|
|
Jan 21
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,900
+6.69%
|
-
|
|
Jan 03
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,154
-1.43%
|
$467,084
$46.18 P/Share
|
|
Jan 03
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,459
-1.36%
|
$67,114
$46.18 P/Share
|
|
Jan 03
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,791
-3.29%
|
$174,386
$46.18 P/Share
|
|
Jan 03
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,340
-2.96%
|
$107,640
$46.18 P/Share
|
|
Jan 02
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,937
-0.76%
|
$492,165
$45.64 P/Share
|
|
Jan 02
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,571
-0.72%
|
$70,695
$45.64 P/Share
|
|
Jan 02
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,083
-1.72%
|
$183,735
$45.64 P/Share
|
|
Jan 02
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,520
-1.55%
|
$113,400
$45.64 P/Share
|